article Open AccessTop 1% cited

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

Clinical Cancer Research · 2016 · Vol. 22(15) · pp. 3764–3773

Melinda L. TelliKirsten M. TimmsJulia ReidBryan T. Hennessy(The University of Texas MD Anderson Cancer Center)Gordon B. Mills(The University of Texas MD Anderson Cancer Center)Kristin C. JensenZoltán Szállási(Harvard University)William T. Barry(Harvard University)Eric P. Winer(Dana-Farber Cancer Institute)Nadine Tung(Harvard University)Steven J. Isakoff(Harvard University)Paula D. Ryan(Massachusetts General Hospital)April Greene-Colozzi(Dana-Farber Cancer Institute)Alexander GutinZaina SangaleDiana IlievChris NeffVictor AbkevichJoshua T. JonesJerry S. LanchburyAnne‐Renee HartmanJudy E. Garber(Harvard University)James M. FordDaniel P. Silver✉(Harvard University)Andrea L. Richardson(Harvard University)

View via DOI Full-text PDF

Abstract

DNA Repair Mechanisms PARP inhibition in cancer therapy BRCA gene mutations in cancerBreast cancerChemotherapyOncologyTriple-negative breast cancerMedicineHomologous recombinationInternal medicineCancerComplete responseTriple negative

MeSH terms

Antineoplastic Combined Chemotherapy ProtocolsFemaleHumansMutationNeoplasm StagingPlatinumPrognosisBiomarkers, TumorOdds RatioTelomereTreatment OutcomeGenes, BRCA1Loss of HeterozygosityAllelic ImbalanceGenes, BRCA2

Citations

1,128

FWCI

36.03

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas